Spotlight on Hematology
Incorporating Best Practices and Advancing Therapeutic Options in the Treatment of Multiple Myeloma
StartActivity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.
Learning Objectives
After completing this program, participants should be able to:- Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
- Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
- Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mass General Hospital
Boston, MA
Mount Sinai Hospital
New York, NY
Cedar Sinai Hospital
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface
Oncology.
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen.
Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.
Dr. Vescio is a Member, Speakers Bureau for Amgen, Celgene, and Takeda.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Activity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.
Learning Objectives
After completing this program, participants should be able to:- Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
- Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
- Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mass General Hospital
Boston, MA
Mount Sinai Hospital
New York, NY
Cedar Sinai Hospital
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface
Oncology.
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen.
Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.
Dr. Vescio is a Member, Speakers Bureau for Amgen, Celgene, and Takeda.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Hematology Presentations
Expert Insights: The Expanding Role of Immunotherapy for the Treatment of Multiple Myeloma - Focus on Antibodies, Antibody-Drug Conjugates, and CAR T-Cells
StartActivity Details
Expires: August 3, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
- Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
- Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
- Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available
Activity Description
Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.
Statement of Educational Need
Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.
Agenda
- Unmet needs
- Monoclonal antibodies
- BiTEs
- Vaccines
- ADCs
- CAR T-cells
Faculty
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company
Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company
Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences
Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through August 3, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Activity Details
Expires: August 3, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
- Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
- Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
- Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available
Activity Description
Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.
Statement of Educational Need
Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.
Agenda
- Unmet needs
- Monoclonal antibodies
- BiTEs
- Vaccines
- ADCs
- CAR T-cells
Faculty
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company
Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company
Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences
Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through August 3, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part B
StartActivity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part A
StartActivity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
CAR T-Cell Practicums: A Discussion of Current Data and the Management of Adverse Events
StartActivity Details
Expires: April 18, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma/myeloma/leukemia.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review the structure and function of CAR T-cells and the mechanism of action in patients with hematologic malignancies
- Review clinical trial data of CAR T-cell–based therapies for the treatment of patients with lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
- Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
- Identify characteristics of patients with acute lymphoblastic leukemia who are appropriate for treatment with CAR T-cell therapy
- Develop strategies to mitigate adverse events that may be encountered with the use of CAR T-cell therapy
Activity Description
This activity is designed to evaluate emerging CAR T data and discuss the challenges of managing CAR T specific adverse events to aid community clinicians who treat patients with lymphoma, myeloma, and leukemia.
Statement of Educational Need
Given the recent approval of various CAR T-cell–based therapies for the treatment of patients with hematologic malignancies, as well as the associated volume of emerging data of both currently approved and emerging CAR T-cell therapies, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage adverse events.
Faculty
Chief
Neumann M. and Mildred E. Harris Professorial Chair
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska
Disclosures
Consulting Fees: AbbVie, Acerta/AstraZeneca, BeiGene, Epizyme, Janssen/Pharmacyclic, Karyopharm, Kite Pharma, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, Verastem
Grants/Research Support: Acerta Pharma, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation, Kite Pharma, Merck, Novartis, Seattle Genetics
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through April 18, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Activity Details
Expires: April 18, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma/myeloma/leukemia.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review the structure and function of CAR T-cells and the mechanism of action in patients with hematologic malignancies
- Review clinical trial data of CAR T-cell–based therapies for the treatment of patients with lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
- Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
- Identify characteristics of patients with acute lymphoblastic leukemia who are appropriate for treatment with CAR T-cell therapy
- Develop strategies to mitigate adverse events that may be encountered with the use of CAR T-cell therapy
Activity Description
This activity is designed to evaluate emerging CAR T data and discuss the challenges of managing CAR T specific adverse events to aid community clinicians who treat patients with lymphoma, myeloma, and leukemia.
Statement of Educational Need
Given the recent approval of various CAR T-cell–based therapies for the treatment of patients with hematologic malignancies, as well as the associated volume of emerging data of both currently approved and emerging CAR T-cell therapies, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage adverse events.
Faculty
Chief
Neumann M. and Mildred E. Harris Professorial Chair
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska
Disclosures
Consulting Fees: AbbVie, Acerta/AstraZeneca, BeiGene, Epizyme, Janssen/Pharmacyclic, Karyopharm, Kite Pharma, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, Verastem
Grants/Research Support: Acerta Pharma, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation, Kite Pharma, Merck, Novartis, Seattle Genetics
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through April 18, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Advances in High-Risk and Relapsed/Refractory Acute Myeloid Leukemia
StartActivity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided By
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Outline the recently modified recommendations for the risk stratification and classification of patients with AML and how this classification impacts treatment decisions
- Incorporate recently approved therapies into clinical treatment of patients with high-risk or relapsed/refractory AML
- Discuss the novel investigational agents under development and review the considerations for their potential clinical use in patients with AML
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for acute myeloid leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with acute myeloid leukemia, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
Conflict of Interest Policy/Disclosure Statement
Dr. Levis receives research funding from Astellas Global Pharma, FujiFilm, and Novartis. Dr. Levis provides consulting/honoraria to Agios, Daiichi-Sankyo, Amgen, Menarini, and Novartis.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Agios, and Astellas.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided By
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Outline the recently modified recommendations for the risk stratification and classification of patients with AML and how this classification impacts treatment decisions
- Incorporate recently approved therapies into clinical treatment of patients with high-risk or relapsed/refractory AML
- Discuss the novel investigational agents under development and review the considerations for their potential clinical use in patients with AML
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for acute myeloid leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with acute myeloid leukemia, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
Conflict of Interest Policy/Disclosure Statement
Dr. Levis receives research funding from Astellas Global Pharma, FujiFilm, and Novartis. Dr. Levis provides consulting/honoraria to Agios, Daiichi-Sankyo, Amgen, Menarini, and Novartis.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Agios, and Astellas.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Emerging Strategies for the Management of Chronic Lymphocytic Leukemia
StartActivity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers
- Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines
- Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL
- Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of chronic lymphocytic leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for chronic lymphocytic leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with chronic lymphocytic leukemia, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Washington DC Veterans Affairs Medical Center
Washington, DC
Conflict of Interest Policy/Disclosure Statement
Dr. Ascensao has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from AstraZeneca and Janssen Biotech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers
- Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines
- Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL
- Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of chronic lymphocytic leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for chronic lymphocytic leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with chronic lymphocytic leukemia, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Washington DC Veterans Affairs Medical Center
Washington, DC
Conflict of Interest Policy/Disclosure Statement
Dr. Ascensao has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from AstraZeneca and Janssen Biotech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Current Trends in Multiple Myeloma: Customizing Treatment Strategies and Optimizing Outcomes
StartActivity Details
1 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.
Learning Objectives
After completing this program, participants should be able to:
- Formulate individualized, evidence-based treatment plans for multiple myeloma patients in the VHA, DoD and MHS settings, by applying current standards of care and appropriately sequencing new agents and combinations while considering expert recommendations, disease and patient characteristics and patient needs/preferences
- Evaluate the latest clinical trial data including the evolution of new classes of therapeutics and how to safely and effectively integrate them into care across the disease spectrum of multiple myeloma
- Describe the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mount Sinai Hospital
New York, NY
Conflict of Interest Policy/Disclosure Statement
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen. Dr. Richter is also a Member, Speakers Bureau, for Janssen and Celgene.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
info@plexuscomm.com
Activity Details
1 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.
Learning Objectives
After completing this program, participants should be able to:
- Formulate individualized, evidence-based treatment plans for multiple myeloma patients in the VHA, DoD and MHS settings, by applying current standards of care and appropriately sequencing new agents and combinations while considering expert recommendations, disease and patient characteristics and patient needs/preferences
- Evaluate the latest clinical trial data including the evolution of new classes of therapeutics and how to safely and effectively integrate them into care across the disease spectrum of multiple myeloma
- Describe the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mount Sinai Hospital
New York, NY
Conflict of Interest Policy/Disclosure Statement
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen. Dr. Richter is also a Member, Speakers Bureau, for Janssen and Celgene.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
info@plexuscomm.com
Expert Guidance on the Latest Developments, Treatment Strategies, and Emerging Clinical Data in the Management of Multiple Myeloma
StartActivity Details
1.0 Contact Hour(s)
Accredited by
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.
Learning Objectives
After completing this program, participants should be able to:
- Apply evidence-based best clinical practices for treating multiple myeloma patients throughout the disease continuum
- Summarize the latest data from finalized and ongoing clinical trials, including the evaluation of new classes of therapeutics and review the contexts for their potential clinical use in patients with multiple myeloma
- Determine the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
Conflict of Interest Policy/Disclosure Statement
Dr. Huff has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.
Consultant: Johnson and Johnson, Sanofi, Karyopharm.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™.
Physicians should claim only credit commensurate with the extent of their
participation in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Amgen, Celgene, and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
1.0 Contact Hour(s)
Accredited by
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.
Learning Objectives
After completing this program, participants should be able to:
- Apply evidence-based best clinical practices for treating multiple myeloma patients throughout the disease continuum
- Summarize the latest data from finalized and ongoing clinical trials, including the evaluation of new classes of therapeutics and review the contexts for their potential clinical use in patients with multiple myeloma
- Determine the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
Conflict of Interest Policy/Disclosure Statement
Dr. Huff has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.
Consultant: Johnson and Johnson, Sanofi, Karyopharm.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™.
Physicians should claim only credit commensurate with the extent of their
participation in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Amgen, Celgene, and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Expert Insights: Current and Future Directions in Chronic and Acute Leukemias
StartActivity Details
Expires: November 14, 2020
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with leukemia.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate clinical data for various TKI-based therapies in patients with CML, including newly diagnosed patients and those in later lines of therapy
- Assess various treatment strategies for patients with relapsed/refractory ALL, in consideration of salvage status, MRD, and cytogenetics
- Compare and contrast therapeutic approaches for newly diagnosed patients with AML, including patients who are both eligible and ineligible for intensive induction chemotherapy
Activity Description
Expert Insights is an accredited, videotaped discussion featuring Dr. Elias Jabbour and Dr. Susan O’Brien highlighting the most clinically relevant data on chronic and acute leukemias presented during a live symposium that was held at the 2019 Society of Hematologic Oncology Annual Meeting.
Statement of Educational Need
Several agents have changed the therapeutic landscape of leukemia (including CML, ALL, and AML), but despite their success, the search for new therapeutic options for these diseases is still important due to the emergence of primary or secondary resistance to treatment in patients and the difficulty of eradicating leukemia stem cells as the main “culprit” of the disease. Therefore, leukemia is still an important area of research aimed at improving the effectiveness of patient treatment. Clinicians must stay up to date of novel agents, combinations, and other strategies in order to maximize patient outcomes.
Topics of Discussion
- CML: Moving Next-Generation TKIs Into Earlier Lines of Therapy
- ALL: How Best to Manage Disease in the Relapsed/Refractory Setting
- AML: Selecting Therapy for Newly Diagnosed Patients
Faculty
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Grants/Research Support, Consultant: AbbVie Inc., Bristol-Myers Squibb Company, Pfizer Inc., Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited
Associate Director for Clinical Services
Chao Family Comprehensive Cancer Center University of California Irvine Medical Center
Irvine, California
Consultant: Alexion, Amgen Inc., Aptose Biosciences Inc., Astellas Pharma US, Inc., Celgene Corporation, Eisai Co., Ltd., GlaxoSmithKline, Janssen Oncology, AbbVie Inc., Vaniam Group LLC, Verastem
Research Support: Acerta Pharma, Kite Pharma, Regeneron Pharmaceuticals
Consultant/Research Support: Gilead Sciences, Inc., Pharmacyclics LLC, TG Therapeutics, Pfizer Inc., Sunesis Pharmaceuticals, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating in and receiving CME credit for this activity.
During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit. Materials will be available online through November 14, 2020.
Statement of Commercial Support
This activity is supported by an independent educational grant from Pfizer Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
Activity Details
Expires: November 14, 2020
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with leukemia.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate clinical data for various TKI-based therapies in patients with CML, including newly diagnosed patients and those in later lines of therapy
- Assess various treatment strategies for patients with relapsed/refractory ALL, in consideration of salvage status, MRD, and cytogenetics
- Compare and contrast therapeutic approaches for newly diagnosed patients with AML, including patients who are both eligible and ineligible for intensive induction chemotherapy
Activity Description
Expert Insights is an accredited, videotaped discussion featuring Dr. Elias Jabbour and Dr. Susan O’Brien highlighting the most clinically relevant data on chronic and acute leukemias presented during a live symposium that was held at the 2019 Society of Hematologic Oncology Annual Meeting.
Statement of Educational Need
Several agents have changed the therapeutic landscape of leukemia (including CML, ALL, and AML), but despite their success, the search for new therapeutic options for these diseases is still important due to the emergence of primary or secondary resistance to treatment in patients and the difficulty of eradicating leukemia stem cells as the main “culprit” of the disease. Therefore, leukemia is still an important area of research aimed at improving the effectiveness of patient treatment. Clinicians must stay up to date of novel agents, combinations, and other strategies in order to maximize patient outcomes.
Topics of Discussion
- CML: Moving Next-Generation TKIs Into Earlier Lines of Therapy
- ALL: How Best to Manage Disease in the Relapsed/Refractory Setting
- AML: Selecting Therapy for Newly Diagnosed Patients
Faculty
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Grants/Research Support, Consultant: AbbVie Inc., Bristol-Myers Squibb Company, Pfizer Inc., Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited
Associate Director for Clinical Services
Chao Family Comprehensive Cancer Center University of California Irvine Medical Center
Irvine, California
Consultant: Alexion, Amgen Inc., Aptose Biosciences Inc., Astellas Pharma US, Inc., Celgene Corporation, Eisai Co., Ltd., GlaxoSmithKline, Janssen Oncology, AbbVie Inc., Vaniam Group LLC, Verastem
Research Support: Acerta Pharma, Kite Pharma, Regeneron Pharmaceuticals
Consultant/Research Support: Gilead Sciences, Inc., Pharmacyclics LLC, TG Therapeutics, Pfizer Inc., Sunesis Pharmaceuticals, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating in and receiving CME credit for this activity.
During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit. Materials will be available online through November 14, 2020.
Statement of Commercial Support
This activity is supported by an independent educational grant from Pfizer Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
Incorporating Best Practices and Advancing Therapeutic Options in the Treatment of Multiple Myeloma
StartActivity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.
Learning Objectives
After completing this program, participants should be able to:- Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
- Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
- Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mass General Hospital
Boston, MA
Mount Sinai Hospital
New York, NY
Cedar Sinai Hospital
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface
Oncology.
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen.
Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.
Dr. Vescio is a Member, Speakers Bureau for Amgen, Celgene, and Takeda.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Activity Details
1.0 Contact Hour(s)
Expires: November 11, 2020
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.
Learning Objectives
After completing this program, participants should be able to:- Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
- Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
- Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mass General Hospital
Boston, MA
Mount Sinai Hospital
New York, NY
Cedar Sinai Hospital
Los Angeles, CA
Conflict of Interest Policy/Disclosure Statement
Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface
Oncology.
Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen.
Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.
Dr. Vescio is a Member, Speakers Bureau for Amgen, Celgene, and Takeda.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grants from Janssen Biotech, Inc. and Celgene.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.